Introduction: The Cardiac Rehabilitation Gap
Cardiovascular disease (CVD) remains the leading cause of death globally, claiming an estimated 17.9 million lives each year according to the World Health Organization. For patients who survive a myocardial infarction, coronary artery bypass graft (CABG), or heart valve procedure, cardiac rehabilitation (CR) is not optional — it is a Class I recommendation from the American Heart Association (AHA) and the European Society of Cardiology (ESC). The evidence is robust: patients who participate in CR are 42% less likely to be readmitted to hospital within 6 to 12 months, and they experience significantly lower cardiovascular mortality.
Yet the numbers tell a troubling story. A 2025 study published in Circulation: Cardiovascular Quality and Outcomes found that between 2017 and 2023, only 24.2% of eligible patients in the United States enrolled in cardiac rehabilitation. Of those who did enroll, fewer than 10% completed the recommended 36 sessions. The average patient completed just 13.9 sessions before dropping out.
The reasons are well-documented: transportation barriers, copay costs, work conflicts, caregiving responsibilities, and the sheer geographic reality that large portions of the United States — and indeed the world — are “cardiac rehab deserts” with no CR center within reasonable driving distance. A 2025 analysis in the Journal of the American Heart Association confirmed that counties with higher social vulnerability scores had significantly worse geographic access to CR facilities.
This is where medical wearables enter the picture — not as a consumer gadget, but as a clinical-grade tool that can extend the reach of cardiac rehabilitation from the clinic into the home. For B2B buyers — hospitals, cardiac centers, rehabilitation networks, and health systems — the opportunity to deploy wearable-enabled hybrid CR programs is both a clinical imperative and a market opportunity.
The Market Opportunity: Wearable-Enabled Cardiac Rehabilitation
The convergence of two fast-growing markets makes cardiac rehabilitation wearables a compelling category for OEM/ODM investment.
The global wearable cardiac devices market was valued at USD 3.87 billion in 2025 and is projected to reach USD 25.97 billion by 2034, growing at a CAGR of 23.57%, according to Straits Research. Home care settings already account for 37.84% of end-use revenue, reflecting the accelerating shift toward remote patient monitoring.
Simultaneously, the cardiac rehabilitation market reached USD 2.59 billion in 2026 and is forecast to grow to USD 3.46 billion by 2031 at a 5.91% CAGR, per Mordor Intelligence. The integration of wearable sensors and remote telemetry into rehab devices is identified as the single most impactful growth driver, contributing an estimated +1.5% to the CAGR forecast.
The Asia-Pacific region is the fastest-growing market for both segments, with cardiac rehabilitation expanding at 6.58% CAGR and wearable cardiac devices at 25.57% CAGR. For OEM/ODM manufacturers based in China and Southeast Asia, this represents a strategic window to serve both domestic and export demand.
What this means for B2B buyers: the market for medical-grade wearables purpose-built for cardiac rehabilitation is underserved. Most existing devices are either consumer-grade fitness trackers (insufficient for clinical CR) or hospital-bound telemetry systems (too expensive and complex for home use). The gap is clear — and fillable.
Clinical Evidence: Why Wearables Work in Cardiac Rehabilitation
The clinical case for wearable-enabled cardiac rehabilitation is no longer theoretical. Multiple randomized controlled trials and systematic reviews have established that remote, wearable-guided CR achieves outcomes comparable to — and in some cases superior to — traditional center-based programs.
Key findings from the literature:
- Equivalent efficacy: A systematic review of 14 randomized trials by Bachmann et al. (2022) found that wearable-supported home CR achieved similar improvements in peak VO₂ and quality-of-life scores as supervised center-based CR.
- Higher completion rates: Rawstorn et al. (2016), published in the Journal of the American Heart Association, demonstrated that remotely monitored wearable-guided home CR achieved 91% program completion versus 74% for gym-based CR, while delivering equivalent improvements in cardiorespiratory fitness.
- Reduced hospitalizations: A 2026 randomized trial published in the Journal of the American College of Cardiology (JACC) found that patients using smartwatch-based ECG monitoring after catheter ablation experienced 53% fewer unplanned hospitalizations (22 vs. 47 events, P = 0.023), despite detecting more arrhythmia recurrences.
- Early decompensation detection: PPG-based wearable monitoring can detect heart rate and heart rate variability (HRV) changes that precede clinical decompensation by 24–72 hours, enabling early intervention before hospitalization becomes necessary.
The AHA’s 2024 scientific statement on cardiac rehabilitation, published in Circulation, explicitly endorsed hybrid (center + home) models and recognized wearable technology as a key enabler for expanding CR access — particularly for women, who experience greater mortality benefits from CR yet face disproportionately higher barriers to participation.
Technology Requirements: What a Cardiac Rehab Wearable Must Deliver
A medical wearable designed for cardiac rehabilitation is not simply a fitness tracker with a heart rate sensor. It must meet a distinct set of clinical and operational requirements:
1. Medical-Grade ECG Monitoring
Continuous single-lead ECG — or, ideally, multi-lead ECG — is the foundation. The device must be capable of detecting arrhythmias including atrial fibrillation, premature ventricular contractions, and ischemic ST-segment changes. Diagnostic accuracy is non-negotiable; the PatSnap 2026 technology landscape report documents that leading AI classifiers now achieve F1 scores of 0.92 for AF detection on wearable ECG data.
2. Real-Time Heart Rate Zone Guidance
Cardiac rehabilitation exercise prescription is based on target heart rate zones — typically 50–85% of heart rate reserve using the Karvonen formula, derived from a symptom-limited exercise test. The wearable must provide real-time feedback when patients exceed or fall below their prescribed zones. For patients on beta-blockers, the device must account for blunted chronotropic response, and for patients with atrial fibrillation, it must handle the inherent variability of PPG-derived heart rate.
3. Multi-Parameter Monitoring
Beyond ECG and heart rate, effective CR wearables increasingly incorporate:
- SpO₂ (blood oxygen saturation) for patients with comorbid COPD or heart failure
- Respiratory rate for detecting early signs of pulmonary congestion
- Activity/accelerometry for quantifying functional capacity and step count
- Heart rate recovery (HRR) — the drop in HR after exercise cessation, a powerful predictor of cardiovascular mortality
- HRV parameters (RMSSD, SDNN) for autonomic nervous system assessment
4. Data Integration and Interoperability
The wearable must integrate with the broader clinical ecosystem. A 2025 market survey found that 82% of U.S. rehabilitation centers require EHR data integration. Support for HL7 FHIR standards, Bluetooth Low Energy (BLE) connectivity to patient smartphones, and cloud-based clinician dashboards are now baseline expectations — not differentiators.
5. Patient-Centric Design
For cardiac rehab patients — who are often older, post-surgical, and managing multiple comorbidities — the device must be:
- Lightweight and comfortable for all-day wear
- Simple to operate (68% of home users prioritize “one-touch operation”)
- Water-resistant for daily living
- Battery life sufficient for at least 24–48 hours of continuous monitoring
- Compliant with ISO 10993 biocompatibility standards for skin-contact materials
Key Wearable Form Factors for Cardiac Rehabilitation
The cardiac rehab wearable landscape spans several form factors, each with distinct clinical applications:
ECG Patch Monitors
Adhesive chest-worn patches provide continuous multi-lead ECG for 7–14 days. These are the workhorses of post-discharge monitoring after MI or CABG, enabling detection of silent ischemia, paroxysmal AF, and other arrhythmias that intermittent clinic ECGs would miss. The PatSnap analysis identifies ECG patches as the highest-density patent cluster in wearable cardiac monitoring.
Wrist-Worn PPG + ECG Devices
Wrist-worn devices combining photoplethysmography (PPG) for continuous heart rate and single-lead ECG for on-demand rhythm recording are the most practical form factor for home-based exercise sessions. They provide real-time heart rate zone guidance during workouts and allow patients to record ECGs when symptoms occur.
Chest Straps with Integrated Sensors
Chest-worn HR monitors with ECG electrodes offer superior signal quality during exercise compared to wrist-based PPG, particularly at higher intensities. They are widely used in supervised CR settings and are increasingly being adapted for home use with BLE connectivity to smartphone apps.
Smart Garments
Textile-integrated sensors — conductive yarn electrodes woven into shirts or vests — represent an emerging category. While patent coverage remains sparse relative to academic output (per PatSnap), this represents a potential white space for OEM innovation, particularly for elderly patients who may find adhesive patches uncomfortable for extended wear.
OEM/ODM Considerations: What to Look for in a Manufacturing Partner
For hospitals, health systems, and distributors seeking to procure or white-label cardiac rehabilitation wearables, selecting the right OEM/ODM partner requires careful evaluation across multiple dimensions:
1. Sensor and Algorithm Expertise
The partner must demonstrate deep expertise in medical-grade ECG and PPG sensor integration. This includes electrode design, signal conditioning, noise rejection (particularly motion artifact), and FDA/CE-compliant algorithm development. Ask for clinical validation data — not just accuracy claims.
2. Regulatory Navigation Capability
The regulatory pathway for cardiac monitoring wearables varies by jurisdiction. In the U.S., most fall under FDA Class II (510(k) pathway). In the EU, they are subject to the Medical Device Regulation (MDR). The OEM partner should be capable of supporting the certification process, including preparation of technical documentation, biocompatibility testing per ISO 10993, and clinical performance evaluation. Look for partners with existing ISO 13485 quality management system certification.
3. Data Security and Privacy Compliance
Cardiac rhythm data is protected health information. The device firmware, companion app, and cloud infrastructure must comply with HIPAA (U.S.), GDPR (EU), and relevant local data protection regulations. End-to-end encryption, secure device-cloud communication, and role-based access control are non-negotiable.
4. Customization Flexibility
The ideal OEM partner offers customization across multiple layers: hardware (sensor configuration, form factor, battery capacity), firmware (algorithms, alert thresholds, data capture protocols), and software (branded companion app, clinician dashboard, EHR integration). The ability to adapt the device to specific clinical workflows — not just rebrand an off-the-shelf product — distinguishes a true ODM partner from a generic contract manufacturer.
5. Scalability and Supply Chain Reliability
With the cardiac rehab wearable market growing at double-digit rates, the manufacturing partner must demonstrate the capacity to scale production while maintaining quality. Evaluate the partner’s component sourcing strategy (particularly for MEMS sensors and low-power MCUs), in-house testing capabilities, and track record of on-time delivery.
6. Cost Efficiency Without Clinical Compromise
While pricing should remain competitive, B2B buyers must recognize that medical-grade wearables carry inherently higher BOM (bill of materials) costs than consumer fitness trackers — driven by clinical-grade sensors, medical-grade materials, and regulatory overhead. The goal is not the lowest unit cost, but the optimal balance of clinical performance, regulatory compliance, and per-patient economics that supports sustainable program deployment.
Implementation Models for Healthcare Providers
For B2B buyers considering deployment, three implementation models have emerged as best practice:
Hybrid CR (Center + Home): Patients begin with 6–12 supervised center-based sessions, then transition to wearable-guided home sessions with asynchronous clinician review. This model preserves the benefits of in-person assessment while dramatically expanding capacity.
Home-First CR: Patients are equipped with wearables at hospital discharge and complete the full 36-session program at home, with synchronous telemonitoring during exercise sessions and weekly virtual check-ins. This model is particularly suited for rural patients and those with transportation barriers.
Maintenance-Phase Monitoring: After completing the formal CR program, patients continue wearing the device for long-term maintenance monitoring, with automated alerts for arrhythmia recurrence or functional decline. This model supports the transition from episodic rehabilitation to continuous cardiovascular disease management.
Conclusion: The Time to Build Is Now
Cardiac rehabilitation is one of the most evidence-backed interventions in cardiovascular medicine — and one of the most underutilized. Medical wearables offer the most practical, scalable solution to the access crisis that leaves 75% of eligible patients without the CR they need.
For B2B buyers — hospital systems, cardiac centers, rehabilitation networks, and international distributors — the market conditions are favorable: growing demand, robust clinical evidence, expanding reimbursement coverage, and an underserved product category. The OEM/ODM partners that move now to develop purpose-built cardiac rehabilitation wearables will be positioned to capture a meaningful share of a market that is projected to exceed USD 25 billion by 2034.
The question is not whether wearable-enabled cardiac rehabilitation will become the standard of care. The question is who will build the devices that make it possible.
Interested in developing or sourcing medical-grade wearables for cardiac rehabilitation? Contact Xdun Medical Technology for OEM/ODM partnership inquiries.
📧 Email: jine@xdunmedical.com
📞 Phone: +86-13544254314
🌐 Website: www.xdunmedical.com
Xdun Medical Technology Co., Ltd. (Shenzhen Geyan Technology) — 28 years of electronics manufacturing experience, 14 years of smart wearable ODM expertise. We support CE, FCC, FDA, ISO 13485 certification pathways and offer full-stack customization from sensor design to cloud platform integration.
References:
WHO Cardiovascular Disease Fact Sheet | AHA Scientific Statement on Cardiac Rehabilitation, Circulation (2024) | Circulation: Cardiovascular Quality and Outcomes (November 2025) | JAHA: Disparities in Geographic Access to CR (October 2025) | JACC: Smartwatch ECG Monitoring After AF Ablation (January 2026) | Straits Research: Wearable Cardiac Devices Market Report (December 2025) | Mordor Intelligence: Cardiac Rehabilitation Market Report (January 2026) | PatSnap: Wearable Cardiac Monitor Technology Landscape (April 2026) | Rawstorn et al., JAHA (2016) | Bachmann et al., Systematic Review of Wearable-Enabled Home CR (2022)